stockportfolio.pro
Stocks / SYK vs VRTX
SYK vs VRTX
Stryker Corporation and Vertex Pharmaceuticals Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Stryker Corporation (SYK) | Vertex Pharmaceuticals Incorporated (VRTX) | |
|---|---|---|
| Market cap | $120.4B | $113.1B |
| Revenue (latest FY) | $25.12B | $12.00B |
| Net income (latest FY) | $3.25B | $3.95B |
| Revenue growth (5y CAGR) | 11.8% | 14.1% |
| Net margin | 12.9% | 32.9% |
| Return on equity | 14.5% | 21.2% |
| P/E ratio | 36.3 | 26.5 |
| Dividend yield | 1.2% | — |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open SYK — free Open VRTX — freeFrequently asked questions
Which is bigger, SYK or VRTX?
Stryker Corporation is larger by market capitalization — $120.4B versus $113.1B.
Which grows faster, SYK or VRTX?
Over the last five fiscal years, Vertex Pharmaceuticals Incorporated grew revenue faster — 14.1%/yr versus 11.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.